A team of Russian scientists has identified the role of the interleukin-6 molecule in the development of allergic asthma. It may be a new target for the treatment of this disease. The results are published in Frontiers in Immunology .
A new study led by researchers at the Columbia Center for Children's Environmental Health (CCCEH) organizes the available scientific evidence on the effects of air pollution on children's health.
Cognitive behavioral therapy (CBT) delivered by respiratory nurses is associated with reduced anxiety symptoms and is cost-effective for patients with chronic obstructive pulmonary disease (COPD), according to a study recently published in ERJ Open Research.
Experimental findings support a connection between mucins in the lung and pulmonary fibrosis. A team of investigators led by members of the University of Colorado School of Medicine faculty at CU Anschutz Medical Campus has identified a connection between mucus in the small airways and pulmonary fibrosis.
Researchers at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression could help predict disease severity and treatment response, and lead to therapies tailored to each patient's precise biology. Findings were published in Physiological Genomics.
Half-facepiece reusable elastomeric respirators are an effective and viable option for protecting health care workers from exposure to airborne transmissible contaminants or infectious agents
Almost no hospitals in the California Veteran's Administration system adhere to national guidelines that recommend the use of a clinical decision rule and D-dimer test before patients with pulmonary embolism are referred for CT pulmonary angiography.
The US Food and Drug Administration (FDA) has approved revefenacin inhalation solution (Yupelri, Theravance Biopharma/Mylan) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Initial research of lung cancer from the study, which will run into early 2019 with in-depth country research and workshops, will be presented by the Economist Intelligence Unit at the European Cancer Forum in Brussels, which is hosted by MSD. The audience of policy-makers, academics, healthcare professionals, industry, and patient representatives, will provide the first sounding-board for the study findings, and help focus the next phase of research. The EIU will be looking to understand whether countries are advancing, innovating and seizing the opportunities to save lives.
The strategy for triggering the patient's own immune system to attack cancer, immunotherapy, is proving useful for more and more tumor types, although to varying degrees. In lung cancer, immunotherapy had proven to extend survival rates for only some variants of the disease.
Now, an international clinical trial which also encompasses professionals has substantially increased the group of lung cancer patients who may benefit from immunotherapy.
Patients with rifampicin-resistant tuberculosis (TB) and resistance to fluoroquinolones and/or injectables who were treated with bedaquiline in an optimized individualized background regimen experienced high rates of successful treatment outcomes, according to study results published in the European Respiratory Journal.
Individuals with chronic breathlessness who were treated with 25 to 100 mg sertraline for 4 weeks showed no improvement in symptomatic relief compared with placebo, according to study results published in the European Respiratory Journal.